Novel coronavirus disease in patients with end‐stage kidney disease
Author:
Affiliation:
1. Medical Corporation JISEIKAI Tachibana Clinic Tokyo Japan
2. Department of Pharmacy, Faculty of Pharmacy Kindai University Osaka Japan
3. Medical Corporation SHOWAKAI Tokyo Japan
Publisher
Wiley
Subject
Nephrology,Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.13599
Reference39 articles.
1. World Health Organization.As of 3:12 pm CEST 3 October 2020 World Health Organization coronavirus disease (COVID‐19) dashboard[cited 2020 Oct 5]. Available from:https://covid19.who.int/
2. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
3. A pneumonia outbreak associated with a new coronavirus of probable bat origin
4. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
5. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19;Nephrology Dialysis Transplantation;2023-07-11
2. Vaccination Against SARS-CoV-2 and Mortality in Hemodialysis Patients: Three is Good;Black Sea Journal of Health Science;2023-07-01
3. Comparative study on albumin, C-Reactive Protein (CRP) and D-dimer in chronic hemodialysis patients with COVID-19;Bali Medical Journal;2023-06-24
4. Comparison of all renal replacement therapy modalities in terms of COVID‐19 infection rate & mortality in the COVID‐19 pandemic and importance of home therapies;Therapeutic Apheresis and Dialysis;2022-10-06
5. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis;American Journal of Kidney Diseases;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3